Spinal Muscular Atrophy (SMA) Carrier Screening in Pregnancy
This payment policy governs coverage and reimbursement for spinal muscular atrophy (SMA) carrier screening (CPT 81329, 81336) for members of Fidelis Care products, specifying when testing is covered and when it is not.
No material clinical or coverage changes in this revision.
Coverage Criteria for SMA Carrier Screening
SMA Carrier Screening Coverage Criteria
Covered when ALL of the following are met:
Noncoverage for nonpregnant women and males per policy statement.
Coding and Frequency
| 81329 | SMN1 deletion analysis; carrier testing (includes SMN2 analysis if performed) |
| 81336 | SMN1 gene full gene sequence analysis |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.